Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serotonin 5-HT7 receptor signaling modulates inflammatory responses and survival after myocardial infarction.

Journal of translational medicine·2026
Same author

Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine.

European journal of heart failure·2026
Same author

Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.

ESC heart failure·2026
Same author

Peripartum cardiomyopathy.

Lancet (London, England)·2025
Same author

Immune dysregulation as a key driver of peripartum cardiomyopathy - an exploratory advanced imaging and biomarker study.

European journal of heart failure·2025
Same author

Cardiac dysfunction related to cardiac mRNA and protein traffic impairment due to reduced unconventional motor protein myosin-5b expression.

European heart journal·2025

Related Experiment Video

Updated: Mar 10, 2026

Amide Hydrogen/Deuterium Exchange & MALDI-TOF Mass Spectrometry Analysis of Pak2 Activation
07:15

Amide Hydrogen/Deuterium Exchange & MALDI-TOF Mass Spectrometry Analysis of Pak2 Activation

Published on: November 26, 2011

18.2K

cUMP hydrolysis by PDE3A.

Stefan Berrisch1, Jessica Ostermeyer1, Volkhard Kaever2

  • 1Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany.

Naunyn-Schmiedeberg'S Archives of Pharmacology
|December 16, 2016
PubMed
Summary

Phosphodiesterase PDE3A efficiently breaks down cyclic uridine monophosphate (cUMP) in cardiomyocytes. This enzyme plays a key role in managing cUMP levels, particularly under disease conditions.

Keywords:
Cyclic UMPHL-1 cellsNeonatal rat cardiomyocytesPDE3APhosphodiesterase

More Related Videos

Preparation of Hydroxy-PAAm Hydrogels for Decoupling the Effects of Mechanotransduction Cues
11:31

Preparation of Hydroxy-PAAm Hydrogels for Decoupling the Effects of Mechanotransduction Cues

Published on: August 28, 2014

14.1K
A Toolkit to Enable Hydrocarbon Conversion in Aqueous Environments
20:28

A Toolkit to Enable Hydrocarbon Conversion in Aqueous Environments

Published on: October 2, 2012

14.7K

Related Experiment Videos

Last Updated: Mar 10, 2026

Amide Hydrogen/Deuterium Exchange & MALDI-TOF Mass Spectrometry Analysis of Pak2 Activation
07:15

Amide Hydrogen/Deuterium Exchange & MALDI-TOF Mass Spectrometry Analysis of Pak2 Activation

Published on: November 26, 2011

18.2K
Preparation of Hydroxy-PAAm Hydrogels for Decoupling the Effects of Mechanotransduction Cues
11:31

Preparation of Hydroxy-PAAm Hydrogels for Decoupling the Effects of Mechanotransduction Cues

Published on: August 28, 2014

14.1K
A Toolkit to Enable Hydrocarbon Conversion in Aqueous Environments
20:28

A Toolkit to Enable Hydrocarbon Conversion in Aqueous Environments

Published on: October 2, 2012

14.7K

Area of Science:

  • Cardiovascular Biology
  • Enzymology
  • Molecular Cardiology

Background:

  • Cardiac phosphodiesterases (PDEs) regulate cyclic nucleotide signaling.
  • PDE3A is known to hydrolyze cyclic adenosine monophosphate (cAMP).
  • Previous studies indicated cUMP-degrading activity in cardiac tissue, but the specific enzymes involved were not fully characterized.

Purpose of the Study:

  • To characterize the enzyme kinetics of PDE3A-mediated cyclic uridine monophosphate (cUMP) hydrolysis.
  • To determine if cUMP and cUMP-hydrolyzing PDEs are present in cardiomyocytes.
  • To investigate the role of PDE3A in cUMP metabolism within cardiac cells.

Main Methods:

  • Enzyme kinetics experiments (time course, inhibitor, Michaelis-Menten) for PDE3A-mediated cUMP hydrolysis.
  • Quantification of intracellular cyclic nucleotide concentrations and PDE mRNA levels in neonatal rat cardiomyocytes (NRCMs) and HL-1 cells.
  • High-performance liquid chromatography (HPLC)-coupled tandem mass spectrometry (MS/MS) for detecting cyclic nucleotide metabolites.

Main Results:

  • PDE3A exhibits low-affinity (KM ~143 μM) and high-velocity (Vmax ~42 μmol/min/mg) hydrolysis of cUMP.
  • PDE3A also hydrolyzes cAMP with high affinity (KM ~0.7 μM) and lower velocity (Vmax ~1.2 μmol/min/mg).
  • Significant levels of cUMP and PDE3A mRNA were detected in NRCMs and HL-1 cells; milrinone inhibited cUMP hydrolysis in cell homogenates.

Conclusions:

  • PDE3A functions as a high-velocity, low-affinity enzyme for cUMP hydrolysis in cardiomyocytes.
  • While PDE3A contributes to cUMP degradation, intact cells may employ additional PDE3-independent pathways.
  • Further research is warranted to explore the biological significance of cUMP in cardiac cells and PDE3A's role in managing elevated cUMP levels during disease.